Literature DB >> 30737967

The impact of dihydropyridine derivatives on the cerebral blood flow response to somatosensory stimulation and spreading depolarization.

Írisz Szabó1, Orsolya M Tóth1, Zsolt Török2,3, Dániel Péter Varga1, Ákos Menyhárt1, Rita Frank1, Dóra Hantosi1, Ákos Hunya3, Ferenc Bari1, Ibolya Horváth2, László Vigh2, Eszter Farkas1.   

Abstract

BACKGROUND AND
PURPOSE: A new class of dihydropyridine derivatives, which act as co-inducers of heat shock protein but are devoid of calcium channel antagonist and vasodilator effects, has recently been developed with the purpose of selectively targeting neurodegeneration. Here, we evaluated the action of one of these novel compounds LA1011 on neurovascular coupling in the ischaemic rat cerebral cortex. As a reference, we applied nimodipine, a vasodilator dihydropyridine and well-known calcium channel antagonist. EXPERIMENTAL APPROACH: Rats were treated with LA1011 or nimodipine, either by chronic, systemic (LA1011), or acute, local administration (LA1011 and nimodipine). In the latter treatment group, global forebrain ischaemia was induced in half of the animals by bilateral common carotid artery occlusion under isoflurane anaesthesia. Functional hyperaemia in the somatosensory cortex was created by mechanical stimulation of the contralateral whisker pad under α-chloralose anaesthesia. Spreading depolarization (SD) events were elicited subsequently by 1 M KCl. Local field potential and cerebral blood flow (CBF) in the parietal somatosensory cortex were monitored by electrophysiology and laser Doppler flowmetry. KEY
RESULTS: LA1011 did not alter CBF, but intensified SD, presumably indicating the co-induction of heat shock proteins, and, perhaps an anti-inflammatory effect. Nimodipine attenuated evoked potentials and SD. In addition to the elevation of baseline CBF, nimodipine augmented hyperaemia in response to both somatosensory stimulation and SD, particularly under ischaemia. CONCLUSIONS AND IMPLICATIONS: In contrast to the CBF improvement achieved with nimodipine, LA1011 seems not to have discernible cerebrovascular effects but may up-regulate the stress response.
© 2019 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30737967      PMCID: PMC6468258          DOI: 10.1111/bph.14611

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  59 in total

1.  Animal research: reporting in vivo experiments: the ARRIVE guidelines.

Authors:  Carol Kilkenny; William Browne; Innes C Cuthill; Michael Emerson; Douglas G Altman
Journal:  Br J Pharmacol       Date:  2010-08       Impact factor: 8.739

2.  Spreading depression as a contributor to ischemic brain damage.

Authors:  M Nedergaard
Journal:  Adv Neurol       Date:  1996

3.  PSD-95 uncoupling from NMDA receptors by Tat- N-dimer ameliorates neuronal depolarization in cortical spreading depression.

Authors:  Krzysztof Kucharz; Ida Søndergaard Rasmussen; Anders Bach; Kristian Strømgaard; Martin Lauritzen
Journal:  J Cereb Blood Flow Metab       Date:  2016-01-01       Impact factor: 6.200

Review 4.  'Second generation' dihydropyridine calcium antagonists. Greater vascular selectivity and some unique applications.

Authors:  D D Freedman; D D Waters
Journal:  Drugs       Date:  1987-11       Impact factor: 9.546

Review 5.  The role of spreading depression, spreading depolarization and spreading ischemia in neurological disease.

Authors:  Jens P Dreier
Journal:  Nat Med       Date:  2011-04-07       Impact factor: 53.440

6.  Correlation between tissue depolarizations and damage in focal ischemic rat brain.

Authors:  R M Dijkhuizen; J P Beekwilder; H B van der Worp; J W Berkelbach van der Sprenkel; K A Tulleken; K Nicolay
Journal:  Brain Res       Date:  1999-09-04       Impact factor: 3.252

7.  Neurovascular regulation in the ischemic brain.

Authors:  Katherine Jackman; Costantino Iadecola
Journal:  Antioxid Redox Signal       Date:  2015-01-10       Impact factor: 8.401

8.  Regulation of inflammatory transcription factors by heat shock protein 70 in primary cultured astrocytes exposed to oxygen-glucose deprivation.

Authors:  J Y Kim; M A Yenari; J E Lee
Journal:  Neuroscience       Date:  2014-12-05       Impact factor: 3.590

9.  High incidence of adverse cerebral blood flow responses to spreading depolarization in the aged ischemic rat brain.

Authors:  Ákos Menyhárt; Péter Makra; Borbála É Szepes; Orsolya M Tóth; Péter Hertelendy; Ferenc Bari; Eszter Farkas
Journal:  Neurobiol Aging       Date:  2015-08-18       Impact factor: 4.673

10.  THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview.

Authors:  Stephen Ph Alexander; Eamonn Kelly; Neil V Marrion; John A Peters; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; O Peter Buneman; John A Cidlowski; Arthur Christopoulos; Anthony P Davenport; Doriano Fabbro; Michael Spedding; Jörg Striessnig; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2017-12       Impact factor: 8.739

View more
  4 in total

Review 1.  Nimodipine Reappraised: An Old Drug With a Future.

Authors:  Andrew P Carlson; Daniel Hänggi; Robert L Macdonald; Claude W Shuttleworth
Journal:  Curr Neuropharmacol       Date:  2020       Impact factor: 7.363

2.  Comparative analysis of spreading depolarizations in brain slices exposed to osmotic or metabolic stress.

Authors:  Ákos Menyhárt; Eszter Farkas; Rita Frank; Ferenc Bari
Journal:  BMC Neurosci       Date:  2021-05-03       Impact factor: 3.288

Review 3.  Tissue Acidosis Associated with Ischemic Stroke to Guide Neuroprotective Drug Delivery.

Authors:  Orsolya M Tóth; Ákos Menyhárt; Rita Frank; Dóra Hantosi; Eszter Farkas; Ferenc Bari
Journal:  Biology (Basel)       Date:  2020-12-11

4.  Aging Impairs Cerebrovascular Reactivity at Preserved Resting Cerebral Arteriolar Tone and Vascular Density in the Laboratory Rat.

Authors:  Armand R Bálint; Tamás Puskás; Ákos Menyhárt; Gábor Kozák; Imre Szenti; Zoltán Kónya; Tamás Marek; Ferenc Bari; Eszter Farkas
Journal:  Front Aging Neurosci       Date:  2019-11-08       Impact factor: 5.750

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.